Market Place
Sourcing Support
Xilio Reveals Pipeline Progress And 2025 Financial Results
23 Mar 2026 //
GLOBENEWSWIRE
Xilio Therapeutics Highlights Upcoming Milestones
08 Jan 2026 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Proposed Public Offering
02 Jun 2025 //
GLOBENEWSWIRE
Xilio Therapeutics Prices $50.0M Public Offering
02 Jun 2025 //
GLOBENEWSWIRE
Xilio Release Ph 2 Data For Vilastobart With Atezolizumab In Cancer
21 Jan 2025 //
GLOBENEWSWIRE
Xilio Announces Inducement Grant Under Nasdaq LR 5635(c)(4)
10 Jan 2025 //
GLOBENEWSWIRE
Xilio Announces Q3 2024 Financial Results & Pipeline Updates
07 Nov 2024 //
GLOBENEWSWIRE
Xilio Appoints Aoife Brennan, James Shannon To Board
13 Jun 2024 //
GLOBENEWSWIRE
Xilio fires 21% of its workforce and reprioritises pipeline
02 Apr 2024 //
PHARMACEUTICAL TECHNOLOGY
Gilead and Xilio Announce License Agreement for Tumor-Activated IL-12 Program
28 Mar 2024 //
BUSINESSWIRE
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
28 Mar 2024 //
GLOBENEWSWIRE
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel
28 Feb 2024 //
GLOBENEWSWIRE
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
31 Jan 2024 //
GLOBENEWSWIRE
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline
08 Jan 2024 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Xilio to Host Virtual Investor Conference Call and Webcast on November 6, 2023
31 Oct 2023 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Upcoming Presentations at the SITC
27 Sep 2023 //
GLOBENEWSWIRE
Xilio to Present at Morgan Stanley 21st Annual Global Healthcare Conference
05 Sep 2023 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Promotion of Katarina Luptakova to CMO
05 Sep 2023 //
GLOBENEWSWIRE
Xilio Announces Promotion of Chris Frankenfield to Chief Operating Officer
03 Aug 2023 //
GLOBENEWSWIRE
Xilio reports preliminary data from Phase I solid tumours therapy trial
26 May 2023 //
CLINICAL TRIALS ARENA
Xilio Therapeutics Announces Pipeline and Business Updates and1Q 2023 FYR
09 May 2023 //
GLOBENEWSWIRE
Xilio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 Apr 2023 //
GLOBENEWSWIRE
Xilio Announces Updates for the Q4 and Full Year 2022 Financial Results
02 Mar 2023 //
GLOBENEWSWIRE
Xilio Therapeutics to Present at Upcoming Investor Conferences
27 Feb 2023 //
GLOBENEWSWIRE
Xilio Therapeutics to Present at Citi 2023 Virtual Oncology Leadership Summit
16 Feb 2023 //
GLOBENEWSWIRE
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
02 Feb 2023 //
GLOBENEWSWIRE
Xilio Therapeutics to Host Program Spotlighting XTX301, a Tumor-Activated IL-12
23 Nov 2022 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Pipeline & Updates and 3Q 2022 Financial Results
09 Nov 2022 //
GLOBENEWSWIRE
Drugs up for sale, on the shelf in biotech pipeline clear-outs
09 Nov 2022 //
FIERCEBIOTECH
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
22 Sep 2022 //
GLOBENEWSWIRE
Xilio Therapeutics to Present at Morgan Stanley 20th Annual GHC
06 Sep 2022 //
GLOBENEWSWIRE
Xilio Announces Prelim PI Dose-Escalation Data for XTX101; Reports Q2`22 results
09 Aug 2022 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
16 Jun 2022 //
GLOBENEWSWIRE
Xilio Therapeutics to Present at H.C. Wainwright Global Investment Conference
18 May 2022 //
GLOBENEWSWIRE
Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer
17 May 2022 //
GLOBENEWSWIRE
Xilio Therapeutics Reports First Quarter 2022 Financial Results
12 May 2022 //
GLOBENEWSWIRE
Xilio Tx to Present at the 21st Annual Needham Virtual Healthcare Conference
07 Apr 2022 //
GLOBENEWSWIRE
Xilio Tx Reports Q4 and Full Year 2021 Financial Results
01 Mar 2022 //
GLOBENEWSWIRE
Xilio Tx to Participate in the Cowen 42nd Annual Healthcare Conference
28 Feb 2022 //
GLOBENEWSWIRE
Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day
03 Feb 2022 //
PRESS RELEASE
Xilio Initiates Patient Dosing in Phase 1/2 Trial of XTX202 for Solid Tumors
20 Jan 2022 //
GLOBENEWSWIRE
Xilio Therapeutics Reports Pipeline and Business Progress and 3Q Results
02 Dec 2021 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Closing of Initial Public Offering
26 Oct 2021 //
GLOBENEWSWIRE
Xilio Therapeutics Announces Pricing of IPO
21 Oct 2021 //
BUSINESSWIRE
FDA clears Xilio’s IND application for XTX202 to treat solid tumors
19 Oct 2021 //
PHARMABIZ
Solid tumor biotech Xilio Therapeutics sets terms for $125 million IPO
18 Oct 2021 //
RENAISSANCECAPITAL
Xilio Therapeutics Announces FDA Clearance of INDA for XTX202
18 Oct 2021 //
BUSINESSWIRE
IPOs get back into gear with filings from LianBio and Xilio
04 Oct 2021 //
ENDPTS
IPOs get back into gear with filings from LianBio and Xilio
04 Oct 2021 //
ENDPTS
Syndax Appoints Martin H. Huber, M.D., to its Board of Directors
15 Sep 2021 //
PRNEWSWIRE
Xilio inks Merck deal to run checkpoint inhibitor combo tri
26 May 2021 //
FIERCE BIOTECH
Xilio Presents Preclinical Tumor-Selective Activity and Tolerability
12 May 2021 //
BUSINESSWIRE
Xilio Presents Preclinical Tumor-Selective Activity Data for XTX101
12 May 2021 //
BIOSPACE
Xilio Therapeutics Strengthens Leadership Team with the Addition of Two
29 Mar 2021 //
BUSINESSWIRE
Xilio Therapeutics Strengthens Leadership Team with the Addition of Two
29 Mar 2021 //
BUSINESSWIRE
Xilio Raises $95 Million in Series C Financing t
24 Feb 2021 //
BUSINESSWIRE
Xilio Therapeutics eyes the fast track to the clinic with $95M in investor cash
24 Feb 2021 //
ENDPTS
Xilio raises $95M to take twists on Yervoy and IL-2 into clinic
24 Feb 2021 //
FIERCE BIOTECH
Xilio to Present Data on Tumor-Selective Immunotherapies at the 2020 (SITC)
10 Nov 2020 //
BIOSPACE
